Global Liquid Biopsy Market By Offering (Testing Services, Kits, Platform, Other consumables), By Technology (Polymerase Chain Reaction (PCR), Next Generation Sequencing (NGS), Others), By Workflow (Sample Preparation, Library Preparation, Sequencing, Data Analysis & Management), By Sample (Blood, Urine, Saliva, Others), By Circulating Biomarkers (Circulating Tumor Cells (CTCs), Cell-free Nucleic Acids, Exosomes & Extracellular Vesicles), By Application (Oncological and Non-oncological), By End User (Clinical Laboratories, Academic & Research Institutes, Pharmaceutical & Biotechnology Companies), By Region Competition Forecast & Opportunities, 2027
Global liquid biopsy market was valued at USD 2,728.57 million in 2021, and during the forecast period, it is expected to expand at a CAGR of 13.77%. An alternate way of detecting and diagnosing cancer is liquid biopsy. The primary reason propelling the growth of the liquid biopsy market is the rising incidence of cancer worldwide. Liquid biopsies aid in the early detection of cancer while traditional biopsy techniques do not allow the detection of cancer in the aged population.
Due to factors such as the rising prevalence of cancer, increased funding for research to find new biomarkers, and increased emphasis on the use of liquid biopsy, the market is anticipated to experience rapid expansion.
The rise of the industry is partly a result of substantial investments made by biotechnology firms in the research and development of liquid biopsies. A further factor driving the growth of the liquid biopsy market in the years to come is the increasing use of liquid biopsy among prominent end users.
Rising Incidence of Cancer
Several factors, including tobacco use, alcohol use, poor food, physical inactivity, and air pollution, are contributing to the rise in cancer cases in the modern world. The global incidence of cancer is rising, making it the second biggest cause of death. Breast cancer is now the most prevalent type of cancer diagnosed worldwide due to the increased prevalence of the disease among females.
Growing adoption of Liquid Biopsy among major end users
As prospective screening, diagnostic, prognostic, and predictive tests in cancer, liquid biopsies have gained a lot of interest. Clinical oncology has undergone a significant revolution owing to liquid biopsy, which makes it easier to sample tumors, provide continuous monitoring through repeated sampling, enable the creation of specific treatment plans, and test for therapeutic resistance. Since most cancers are in contact with blood, liquid biopsy mostly includes blood collection, though mucosa, pleural effusions, urine, and cerebrospinal fluid (CSF) are also examined during the procedure. As a result, Liquid Biopsy offers improved diagnosis sensitivity and simplicity of recurring sampling throughout therapy in a far more practical and non-invasive manner.
Increased Awareness Regarding Cancer
Today's population is more aware of the signs and symptoms of cancer, and they try to have their illness diagnosed when it is still in its early stages. As a result of early cancer detection, tumor progression monitoring, and clinical prognosis assessment capabilities, liquid biopsy technology is experiencing market expansion.
Market Segmentation
The Global Liquid Biopsy Market is segmented based on Offering, Technology, Workflow, Sample, Circulating Biomarker, Application, End User, and Region. Based on Offering, the market can be split into Testing Service, Kits, Platform, Other Consumables. Based on Technology, the market can be divided into Next Generation Sequencing, Polymerase Chain Reactions, Others. Based on Workflow, the market is divided into Sample Preparation, Library Preparation, Sequencing, Data Analysis & Management. Based on Sample, the market is divided into Blood, Urine, Saliva, Others.
Based on Circulating Biomarker, the market is divided into Circulating Tumor Cells (CTCs), Cell Free RNAs, Exosomes & Extracellular Vesicles, Others. In terms of Application, the market can be categorized into Oncological v/s non-Oncological. Based on End User, the market is split into Pharmaceutical & Biotechnology Companies, Clinical Laboratories, Academic & Research Institutes.
Company Profiles
F. Hoffmann-La Roche AG, Thermo Fisher Scientific, Inc., PerkinElmer Inc., LungLife AI, Inc., Illumina, Inc., QIAGEN NV, NeoGenomics Laboratories, Inc., Myriad Genetics, Inc., Biocept, Inc., Bio-Rad Laboratories, Inc., Guardant Health Inc., Natera, Inc., Sysmex Corporation, Abcodia Ltd., Dxcover Limited are among some of the major market players in the Global Liquid Biopsy Market.
Report Scope:
In this report, Global Liquid Biopsy Market has been segmented into following categories, in addition to the industry trends which have also been detailed below:
- Liquid Biopsy Market, By Offering:
- Testing Service
- Kits
- Platform
- Other consumables
- Liquid Biopsy Market, By Technology:
- Polymerase Chain Reaction
- Next Generation Sequencing
- Others
- Liquid Biopsy Market, By Workflow:
- Sample Preparation
- Library Preparation
- Sequencing
- Data Analysis & Management
- Liquid Biopsy Market, By Sample:
- Blood
- Urine
- Saliva
- Others
- Liquid Biopsy Market, By Circulating Biomarkers:
- Circulating Tumor Cells (CTCs)
- Cell-free Nucleic Acids
- Exosomes & Extracellular Vesicles
- Others
- Liquid Biopsy Market, By Application:
- Oncological
- Non- Oncological
- Liquid Biopsy Market, By Region:
- North America
Canada
Mexico
- Europe
France
United Kingdom
Italy
Spain
Netherlands
Belgium
Denmark
- Asia-Pacific
India
Japan
South Korea
Australia
New Zealand
- South America
Argentina
Colombia
- Middle East & Africa
Egypt
Saudi Arabia
South Africa
UAE
Competitive Landscape:
Company Profiles: Detailed analysis of the major companies present in Global Liquid Biopsy market.
Company Information
- Detailed analysis and profiling of additional market players (up to five).
- 1. Product Overview
- 2. Research Methodology
- 3. Executive Summary
- 4. Impact of COVID-19 on Global Liquid Biopsy Market
- 5. Voice of Customer
- 5.1. Cancer Prevalence, By Gender
- 5.2. Cancer Prevalence, By Age Group
- 5.3. Cancer Prevalence, By Region
- 5.4. Common Methods Used for Cancer Detection
- 5.5. Benefits of Using Liquid Biopsy
- 5.6. Barriers to Adoption of Liquid Biopsy
- 6. Clinical Trial Analysis
- 7. Patent Analysis
- 8. Global Liquid Biopsy Market Outlook
- 8.1. Market Size & Forecast
- 8.1.1. By Value
- 8.2. Market Share & Forecast
- 8.2.1. By Offering (Testing Service, Kits, Platform, Other Consumables)
- 8.2.2. By Technology (Polymerase Chain Reactions, Next Generation Sequencing, Others)
- 8.2.3. By Workflow (Sample Preparation, Library Preparation, Sequencing, Data Analysis & Management)
- 8.2.4. By Sample (Blood, Urine, Saliva, Others)
- 8.2.5. By Circulating Biomarker (Circulating Tumor Cells (CTCs), Cell Free Nucleic Acids, Exosomes & Extracellular Vesicles, Others)
- 8.2.6. By Application (Oncological v/s non-Oncological)
- 8.2.6.1. By Oncological (Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Others)
- 8.2.6.2. By Non-Oncological (Treatment Monitoring, Prognosis & Recurrence Monitoring, Treatment Selection, Others)
- 8.2.7. By End User (Clinical Laboratories, Academic & Research Institutes, Pharmaceutical & Biotechnology Companies)
- 8.2.8. By Company (2021)
- 8.2.9. By Region
- 8.3. Market Map
- 9. North America Liquid Biopsy Market Outlook
- 9.1. Market Size & Forecast
- 9.1.1. By Value
- 9.2. Market Share & Forecast
- 9.2.1. By Offering (Testing Service, Kits, Platform, Other Consumables)
- 9.2.2. By Technology (Polymerase Chain Reactions, Next Generation Sequencing, Others)
- 9.2.3. By Workflow (Sample Preparation, Library Preparation, Sequencing, Data Analysis & Management)
- 9.2.4. By Sample (Blood, Urine, Saliva, Others)
- 9.2.5. By Circulating Biomarker (Circulating Tumour Cells (CTCs), Cell Free Nucleic Acids, Exosomes & Extracellular Vesicles, Others)
- 9.2.6. By Application (Oncological v/s non-Oncological)
- 9.2.6.1. By Oncological (Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Others)
- 9.2.6.2. By Non-Oncological (Treatment Monitoring, Prognosis & Recurrence Monitoring, Treatment Selection, Others)
- 9.2.7. By End User (Clinical Laboratories, Academic & Research Institutes, Pharmaceutical & Biotechnology Companies)
- 9.2.8. By Country
- 9.3. North America: Country Analysis
- 9.3.1. United States Liquid Biopsy Market Outlook
- 9.3.1.1. Market Size & Forecast
- 9.3.1.1.1. By Value
- 9.3.1.2. Market Share & Forecast
- 9.3.1.2.1. By Offering
- 9.3.1.2.2. By Technology
- 9.3.1.2.3. By Workflow
- 9.3.1.2.4. By Sample
- 9.3.1.2.5. By Circulating Biomarker
- 9.3.1.2.6. By Application
- 9.3.1.2.7. By End User
- 9.3.2. Canada Liquid Biopsy Market Outlook
- 9.3.2.1. Market Size & Forecast
- 9.3.2.1.1. By Value
- 9.3.2.2. Market Share & Forecast
- 9.3.2.2.1. By Offering
- 9.3.2.2.2. By Technology
- 9.3.2.2.3. By Workflow
- 9.3.2.2.4. By Sample
- 9.3.2.2.5. By Circulating Biomarker
- 9.3.2.2.6. By Application
- 9.3.2.2.7. By End User
- 9.3.3. Mexico Liquid Biopsy Market Outlook
- 9.3.3.1. Market Size & Forecast
- 9.3.3.1.1. By Value
- 9.3.3.2. Market Share & Forecast
- 9.3.3.2.1. By Offering
- 9.3.3.2.2. By Technology
- 9.3.3.2.3. By Workflow
- 9.3.3.2.4. By Sample
- 9.3.3.2.5. By Circulating Biomarker
- 9.3.3.2.6. By Application
- 9.3.3.2.7. By End User
- 10. Europe Liquid Biopsy Market Outlook
- 10.1. Market Size & Forecast
- 10.1.1. By Value
- 10.2. Market Share & Forecast
- 10.2.1. By Offering (Testing Service, Kits, Platform, Other Consumables)
- 10.2.2. By Technology (Polymerase Chain Reactions, Next Generation Sequencing, Others)
- 10.2.3. By Workflow (Sample Preparation, Library Preparation, Sequencing, Data Analysis & Management)
- 10.2.4. By Sample (Blood, Urine, Saliva, Others)
- 10.2.5. By Circulating Biomarker (Circulating Tumor Cells (CTCs), Cell Free Nucleic Acids, Exosomes & Extracellular Vesicles, Others)
- 10.2.6. By Application (Oncological v/s non-Oncological)
- 10.2.6.1. By Oncological (Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Others)
- 10.2.6.2. By Non-Oncological (Treatment Monitoring, Prognosis & Recurrence Monitoring, Treatment Selection, Others)
- 10.2.7. By End User (Academic & Research Institutes, Clinical Laboratories, , Pharmaceutical & Biotechnology Companies)
- 10.2.8. By Country
- 10.3. Europe: Country Analysis
- 10.3.1. Germany Liquid Biopsy Market Outlook
- 10.3.1.1. Market Size & Forecast
- 10.3.1.1.1. By Value
- 10.3.1.2. Market Share & Forecast
- 10.3.1.2.1. By Offering
- 10.3.1.2.2. By Technology
- 10.3.1.2.3. By Workflow
- 10.3.1.2.4. By Sample
- 10.3.1.2.5. By Circulating Biomarker
- 10.3.1.2.6. By Application
- 10.3.1.2.7. By End User
- 10.3.2. France Liquid Biopsy Market Outlook
- 10.3.2.1. Market Size & Forecast
- 10.3.2.1.1. By Value
- 10.3.2.2. Market Share & Forecast
- 10.3.2.2.1. By Offering
- 10.3.2.2.2. By Technology
- 10.3.2.2.3. By Workflow
- 10.3.2.2.4. By Sample
- 10.3.2.2.5. By Circulating Biomarker
- 10.3.2.2.6. By Application
- 10.3.2.2.7. By End User
- 10.3.3. United Kingdom Liquid Biopsy Market Outlook
- 10.3.3.1. Market Size & Forecast
- 10.3.3.1.1. By Value
- 10.3.3.2. Market Share & Forecast
- 10.3.3.2.1. By Offering
- 10.3.3.2.2. By Technology
- 10.3.3.2.3. By Workflow
- 10.3.3.2.4. By Sample
- 10.3.3.2.5. By Circulating Biomarker
- 10.3.3.2.6. By Application
- 10.3.3.2.7. By End User
- 10.3.4. Italy Liquid Biopsy Market Outlook
- 10.3.4.1. Market Size & Forecast
- 10.3.4.1.1. By Value
- 10.3.4.2. Market Share & Forecast
- 10.3.4.2.1. By Offering
- 10.3.4.2.2. By Technology
- 10.3.4.2.3. By Workflow
- 10.3.4.2.4. By Sample
- 10.3.4.2.5. By Circulating Biomarker
- 10.3.4.2.6. By Application
- 10.3.4.2.7. By End User
- 10.3.5. Spain Liquid Biopsy Market Outlook
- 10.3.5.1. Market Size & Forecast
- 10.3.5.1.1. By Value
- 10.3.5.2. Market Share & Forecast
- 10.3.5.2.1. By Offering
- 10.3.5.2.2. By Technology
- 10.3.5.2.3. By Workflow
- 10.3.5.2.4. By Sample
- 10.3.5.2.5. By Circulating Biomarker
- 10.3.5.2.6. By Application
- 10.3.5.2.7. By End User
- 10.3.6. Netherlands Liquid Biopsy Market Outlook
- 10.3.6.1. Market Size & Forecast
- 10.3.6.1.1. By Value
- 10.3.6.2. Market Share & Forecast
- 10.3.6.2.1. By Offering
- 10.3.6.2.2. By Technology
- 10.3.6.2.3. By Workflow
- 10.3.6.2.4. By Sample
- 10.3.6.2.5. By Circulating Biomarker
- 10.3.6.2.6. By Application
- 10.3.6.2.7. By End User
- 10.3.7. Belgium Liquid Biopsy Market Outlook
- 10.3.7.1. Market Size & Forecast
- 10.3.7.1.1. By Value
- 10.3.7.2. Market Share & Forecast
- 10.3.7.2.1. By Offering
- 10.3.7.2.2. By Technology
- 10.3.7.2.3. By Workflow
- 10.3.7.2.4. By Sample
- 10.3.7.2.5. By Circulating Biomarker
- 10.3.7.2.6. By Application
- 10.3.7.2.7. By End User
- 10.3.8. Denmark Liquid Biopsy Market Outlook
- 10.3.8.1. Market Size & Forecast
- 10.3.8.1.1. By Value
- 10.3.8.2. Market Share & Forecast
- 10.3.8.2.1. By Offering
- 10.3.8.2.2. By Technology
- 10.3.8.2.3. By Workflow
- 10.3.8.2.4. By Sample
- 10.3.8.2.5. By Circulating Biomarker
- 10.3.8.2.6. By Application
- 10.3.8.2.7. By End User
- 11. Asia-Pacific Liquid Biopsy Market Outlook
- 11.1. Market Size & Forecast
- 11.1.1. By Value
- 11.2. Market Share & Forecast
- 11.2.1. By Offering (Testing Service, Kits, Platform, Other Consumables)
- 11.2.2. By Technology (Polymerase Chain Reactions, Next Generation Sequencing, Others)
- 11.2.3. By Workflow (Sample Preparation, Library Preparation, Sequencing, Data Analysis & Management)
- 11.2.4. By Sample (Blood, Urine, Saliva, Others)
- 11.2.5. By Circulating Biomarker (Circulating Tumor Cells (CTCs), Cell Free Nucleic Acids, Exosomes & Extracellular Vesicles, Others)
- 11.2.6. By Application (Oncological v/s non-Oncological)
- 11.2.6.1. By Oncological (Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Others)
- 11.2.6.2. By Non-Oncological (Treatment Monitoring, Prognosis & Recurrence Monitoring, Treatment Selection, Others)
- 11.2.7. By End User (Clinical Laboratories, Academic & Research Institutes, Pharmaceutical & Biotechnology Companies)
- 11.2.8. By Country
- 11.3. Asia-Pacific: Country Analysis
- 11.3.1. China Liquid Biopsy Market Outlook
- 11.3.1.1. Market Size & Forecast
- 11.3.1.1.1. By Value
- 11.3.1.2. Market Share & Forecast
- 11.3.1.2.1. By Offering
- 11.3.1.2.2. By Technology
- 11.3.1.2.3. By Workflow
- 11.3.1.2.4. By Sample
- 11.3.1.2.5. By Circulating Biomarker
- 11.3.1.2.6. By Application
- 11.3.1.2.7. By End User
- 11.3.2. India Liquid Biopsy Market Outlook
- 11.3.2.1. Market Size & Forecast
- 11.3.2.1.1. By Value
- 11.3.2.2. Market Share & Forecast
- 11.3.2.2.1. By Offering
- 11.3.2.2.2. By Technology
- 11.3.2.2.3. By Workflow
- 11.3.2.2.4. By Sample
- 11.3.2.2.5. By Circulating Biomarker
- 11.3.2.2.6. By Application
- 11.3.2.2.7. By End User
- 11.3.3. Japan Liquid Biopsy Market Outlook
- 11.3.3.1. Market Size & Forecast
- 11.3.3.1.1. By Value
- 11.3.3.2. Market Share & Forecast
- 11.3.3.2.1. By Offering
- 11.3.3.2.2. By Technology
- 11.3.3.2.3. By Workflow
- 11.3.3.2.4. By Sample
- 11.3.3.2.5. By Circulating Biomarker
- 11.3.3.2.6. By Application
- 11.3.3.2.7. By End User
- 11.3.4. South Korea Liquid Biopsy Market Outlook
- 11.3.4.1. Market Size & Forecast
- 11.3.4.1.1. By Value
- 11.3.4.2. Market Share & Forecast
- 11.3.4.2.1. By Offering
- 11.3.4.2.2. By Technology
- 11.3.4.2.3. By Workflow
- 11.3.4.2.4. By Sample
- 11.3.4.2.5. By Circulating Biomarker
- 11.3.4.2.6. By Application
- 11.3.4.2.7. By End User
- 11.3.5. Australia Liquid Biopsy Market Outlook
- 11.3.5.1. Market Size & Forecast
- 11.3.5.1.1. By Value
- 11.3.5.2. Market Share & Forecast
- 11.3.5.2.1. By Offering
- 11.3.5.2.2. By Technology
- 11.3.5.2.3. By Workflow
- 11.3.5.2.4. By Sample
- 11.3.5.2.5. By Circulating Biomarker
- 11.3.5.2.6. By Application
- 11.3.5.2.7. By End User
- 11.3.6. New Zealand Liquid Biopsy Market Outlook
- 11.3.6.1. Market Size & Forecast
- 11.3.6.1.1. By Value
- 11.3.6.2. Market Share & Forecast
- 11.3.6.2.1. By Offering
- 11.3.6.2.2. By Technology
- 11.3.6.2.3. By Workflow
- 11.3.6.2.4. By Sample
- 11.3.6.2.5. By Circulating Biomarker
- 11.3.6.2.6. By Application
- 11.3.6.2.7. By End User
- 12. South America Liquid Biopsy Market Outlook
- 12.1. Market Size & Forecast
- 12.1.1. By Value
- 12.2. Market Share & Forecast
- 12.2.1. By Offering (Testing Service, Kits, Platform, Other Consumables)
- 12.2.2. By Technology (Next Generation Sequencing, Polymerase Chain Reactions, Others)
- 12.2.3. By Workflow (Sample Preparation, Library Preparation, Sequencing, Data Analysis & Management)
- 12.2.4. By Sample (Blood, Urine, Saliva, Others)
- 12.2.5. By Circulating Biomarker (Circulating Tumour Cells (CTCs), Cell Free Nucleic Acids, Exosomes & Extracellular Vesicles, Others)
- 12.2.6. By Application (Oncological v/s non-Oncological)
- 12.2.6.1. By Oncological (Breast Cancer, Prostate Cancer, Lung Cancer, Colorectal Cancer, Others)
- 12.2.6.2. By Non-Oncological (Treatment Monitoring, Prognosis & Recurrence Monitoring, Treatment Selection, Others)
- 12.2.7. By End User (Pharmaceutical & Biotechnology Companies, Clinical Laboratories, Academic & Research Institutions)
- 12.2.8. By Country
- 12.3. South America: Country Analysis
- 12.3.1. Brazil Liquid Biopsy Market Outlook
- 12.3.1.1. Market Size & Forecast
- 12.3.1.1.1. By Value
- 12.3.1.2. Market Share & Forecast
- 12.3.1.2.1. By Offering
- 12.3.1.2.2. By Technology
- 12.3.1.2.3. By Workflow
- 12.3.1.2.4. By Sample
- 12.3.1.2.5. By Circulating Biomarker
- 12.3.1.2.6. By Application
- 12.3.1.2.7. By End User
- 12.3.2. Argentina Liquid Biopsy Market Outlook
- 12.3.2.1. Market Size & Forecast
- 12.3.2.1.1. By Value
- 12.3.2.2. Market Share & Forecast
- 12.3.2.2.1. By Offering
- 12.3.2.2.2. By Technology
- 12.3.2.2.3. By Workflow
- 12.3.2.2.4. By Sample
- 12.3.2.2.5. By Circulating Biomarker
- 12.3.2.2.6. By Application
- 12.3.2.2.7. By End User
- 12.3.3. Colombia Liquid Biopsy Market Outlook
- 12.3.3.1. Market Size & Forecast
- 12.3.3.1.1. By Value
- 12.3.3.2. Market Share & Forecast
- 12.3.3.2.1. By Offering
- 12.3.3.2.2. By Technology
- 12.3.3.2.3. By Workflow
- 12.3.3.2.4. By Sample
- 12.3.3.2.5. By Circulating Biomarker
- 12.3.3.2.6. By Application
- 12.3.3.2.7. By End User
- 13. Middle East and Africa Liquid Biopsy Market Outlook
- 13.1. Market Size & Forecast
- 13.1.1. By Value
- 13.2. Market Share & Forecast
- 13.2.1. By Offering (Testing Service, Kits, Platform, Other Consumables)
- 13.2.2. By Technology (Next Generation Sequencing, Polymerase Chain Reactions, Others)
- 13.2.3. By Workflow (Sample Preparation, Library Preparation, Sequencing, Data Analysis & Management)
- 13.2.4. By Sample (Blood, Urine, Saliva, Others)
- 13.2.5. By Circulating Biomarker (Circulating Tumour Cells (CTCs), Circulating Cell Free RNAs, Exosomes & Extracellular Vesicles, Others)
- 13.2.6. By Application (Oncological v/s non-Oncological)
- 13.2.6.1. By Oncological (Breast Cancer, Prostate Cancer, Lung Cancer, Colorectal Cancer, Others)
- 13.2.6.2. By Non-Oncological (Treatment Monitoring, Prognosis & Recurrence Monitoring, Treatment Selection, Others)
- 13.2.7. By End User (Pharmaceutical & Biotechnology Companies, Clinical Laboratories, Academic & Research Institutions)
- 13.2.8. By Country
- 13.3. MEA: Country Analysis
- 13.3.1. Turkey Liquid Biopsy Market Outlook
- 13.3.1.1. Market Size & Forecast
- 13.3.1.1.1. By Value
- 13.3.1.2. Market Share & Forecast
- 13.3.1.2.1. By Offering
- 13.3.1.2.2. By Technology
- 13.3.1.2.3. By Workflow
- 13.3.1.2.4. By Sample
- 13.3.1.2.5. By Circulating Biomarker
- 13.3.1.2.6. By Application
- 13.3.1.2.7. By End User
- 13.3.2. Egypt Liquid Biopsy Market Outlook
- 13.3.2.1. Market Size & Forecast
- 13.3.2.1.1. By Value
- 13.3.2.2. Market Share & Forecast
- 13.3.2.2.1. By Offering
- 13.3.2.2.2. By Technology
- 13.3.2.2.3. By Workflow
- 13.3.2.2.4. By Sample
- 13.3.2.2.5. By Circulating Biomarker
- 13.3.2.2.6. By Application
- 13.3.2.2.7. By End User
- 13.3.3. Saudi Arabia Liquid Biopsy Market Outlook
- 13.3.3.1. Market Size & Forecast
- 13.3.3.1.1. By Value
- 13.3.3.2. Market Share & Forecast
- 13.3.3.2.1. By Offering
- 13.3.3.2.2. By Technology
- 13.3.3.2.3. By Workflow
- 13.3.3.2.4. By Sample
- 13.3.3.2.5. By Circulating Biomarker
- 13.3.3.2.6. By Application
- 13.3.3.2.7. By End User
- 13.3.4. South Africa Liquid Biopsy Market Outlook
- 13.3.4.1. Market Size & Forecast
- 13.3.4.1.1. By Value
- 13.3.4.2. Market Share & Forecast
- 13.3.4.2.1. By Offering
- 13.3.4.2.2. By Technology
- 13.3.4.2.3. By Workflow
- 13.3.4.2.4. By Sample
- 13.3.4.2.5. By Circulating Biomarker
- 13.3.4.2.6. By Application
- 13.3.4.2.7. By End User
- 13.3.5. UAE Liquid Biopsy Market Outlook
- 13.3.5.1. Market Size & Forecast
- 13.3.5.1.1. By Value
- 13.3.5.2. Market Share & Forecast
- 13.3.5.2.1. By Offering
- 13.3.5.2.2. By Technology
- 13.3.5.2.3. By Workflow
- 13.3.5.2.4. By Sample
- 13.3.5.2.5. By Circulating Biomarker
- 13.3.5.2.6. By Application
- 13.3.5.2.7. By End User
- 14. Market Dynamics
- 14.1. Drivers
- 14.2. Challenges
- 15. Market Trends & Developments
- 16. Competitive Landscape (Inclusive of SWOT Analysis)
- 16.1. F. Hoffmann-La Roche AG
- 16.2. Thermo Fisher Scientific, Inc.
- 16.3. PerkinElmer Inc.
- 16.4. LungLife AI, Inc.
- 16.5. Illumina, Inc.
- 16.6. QIAGEN NV
- 16.7. NeoGenomics Laboratories, Inc.
- 16.8. Myriad Genetics, Inc.
- 16.9. Biocept, Inc.
- 16.10. Bio-Rad Laboratories, Inc.
- 16.11. Guardant Health Inc.
- 16.12. Natera, Inc.
- 16.13. Sysmex Corporation
- 16.14. Abcodia Ltd.
- 16.15. Dxcover Limited
- 17. Strategic Recommendations
- 18. About Us & Disclaimer
Research Assistance
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook